[go: up one dir, main page]

FI20000516A7 - Bis-indolylmaleimidderivat samt deras framställning - Google Patents

Bis-indolylmaleimidderivat samt deras framställning Download PDF

Info

Publication number
FI20000516A7
FI20000516A7 FI20000516A FI20000516A FI20000516A7 FI 20000516 A7 FI20000516 A7 FI 20000516A7 FI 20000516 A FI20000516 A FI 20000516A FI 20000516 A FI20000516 A FI 20000516A FI 20000516 A7 FI20000516 A7 FI 20000516A7
Authority
FI
Finland
Prior art keywords
bis
preparation
indolylmaleimide derivatives
indolylmaleimide
derivatives
Prior art date
Application number
FI20000516A
Other languages
English (en)
Finnish (fi)
Inventor
Michael Robert Jirousek
Iii John Hampton Mcdonald
Christopher John Rito
Jr William Francis Heath
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI20000516A7 publication Critical patent/FI20000516A7/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI20000516A 1993-12-07 2000-03-07 Bis-indolylmaleimidderivat samt deras framställning FI20000516A7 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US31697394A 1994-10-03 1994-10-03

Publications (1)

Publication Number Publication Date
FI20000516A7 true FI20000516A7 (sv) 2000-03-07

Family

ID=26859318

Family Applications (3)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (sv) 1993-12-07 1994-12-02 Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat
FI20000516A FI20000516A7 (sv) 1993-12-07 2000-03-07 Bis-indolylmaleimidderivat samt deras framställning
FI20011109A FI20011109A7 (sv) 1993-12-07 2001-05-28 Bis-indolylsuccinimidderivat samt deras framställning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (sv) 1993-12-07 1994-12-02 Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20011109A FI20011109A7 (sv) 1993-12-07 2001-05-28 Bis-indolylsuccinimidderivat samt deras framställning

Country Status (30)

Country Link
US (1) US5698578A (sv)
EP (1) EP0657458B1 (sv)
JP (2) JP3581731B2 (sv)
KR (1) KR100340159B1 (sv)
CN (2) CN1050844C (sv)
AT (1) ATE204579T1 (sv)
AU (1) AU687909B2 (sv)
BR (1) BR9404831A (sv)
CA (1) CA2137203C (sv)
CO (1) CO4340622A1 (sv)
CY (1) CY2413B1 (sv)
CZ (1) CZ291950B6 (sv)
DE (1) DE69428025T2 (sv)
DK (1) DK0657458T3 (sv)
ES (1) ES2162843T3 (sv)
FI (3) FI108138B (sv)
GR (1) GR3037087T3 (sv)
HU (1) HU219709B (sv)
IL (1) IL111850A (sv)
MY (1) MY125587A (sv)
NO (1) NO308798B1 (sv)
NZ (1) NZ270048A (sv)
PE (1) PE49195A1 (sv)
PL (1) PL182124B1 (sv)
PT (1) PT657458E (sv)
RU (1) RU2147304C1 (sv)
SG (1) SG63570A1 (sv)
TW (1) TW425397B (sv)
UA (1) UA44690C2 (sv)
YU (1) YU49200B (sv)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
ATE191219T1 (de) 1995-11-20 2000-04-15 Lilly Co Eli Zwischenprodukte und ihre anwendung für die herstellung von n,n'-überbrückten bisindolylmaleimiden
PE22798A1 (es) * 1995-11-20 1998-05-11 Lilly Co Eli Inhibidor de proteina quinasa c
CA2249205A1 (en) * 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
AU736333B2 (en) * 1996-05-01 2001-07-26 Eli Lilly And Company Therapeutic treatment for VEGF related diseases
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
WO1997041127A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Halo-substituted protein kinase c inhibitors
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
CN1231607A (zh) * 1996-08-30 1999-10-13 伊莱利利公司 利用pkg抑制剂来生产治疗与hiv感染相关的中枢神经系统疾病的药物的用途
WO1998008510A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
US6620977B1 (en) 1998-01-30 2003-09-16 Daiso Co., Ltd. Process for producing butanetriol derivative
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
WO1999047522A1 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
CA2431187A1 (en) * 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
JP2005516968A (ja) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
ES2338789T3 (es) 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
DE602005005787T2 (de) * 2004-01-19 2009-04-30 Novartis Ag Indolylmaleimidderivate
AU2005221283C1 (en) * 2004-03-17 2011-02-03 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7759331B2 (en) 2006-03-10 2010-07-20 Janssen Pharmaceutica Nv Pyridine-containing macroheterococylic compounds as kinase inhibitors
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
JP2013523678A (ja) 2010-03-30 2013-06-17 ノバルティス アーゲー 慢性的に活性なｂ細胞受容体シグナル伝達を有するｂ細胞リンパ腫の治療用のｐｋｃ阻害薬
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
AU2013352379B2 (en) 2012-11-29 2018-09-06 Novartis Ag Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3317285B1 (en) 2015-07-02 2021-01-27 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RS65593B1 (sr) 2015-07-06 2024-06-28 Turning Point Therapeutics Inc Polimorf diaril makrocikla
PL3733187T3 (pl) * 2015-07-21 2025-01-07 Turning Point Therapeutics, Inc. Chiralny makrocykl diarylowy i jego zastosowanie w leczeniu raka
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
PL3658148T3 (pl) 2017-07-28 2024-10-07 Turning Point Therapeutics, Inc. Związki makrocykliczne i ich zastosowania
AU2018392332B2 (en) 2017-12-19 2023-08-03 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating disease
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
EP4654966A1 (en) * 2023-01-27 2025-12-03 Mellicell, Inc. Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
WO2024220957A1 (en) * 2023-04-21 2024-10-24 4M Therapeutics Inc. Polymorphs of n-desmethyl ruboxistaurin and salts thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
FR2614022B1 (fr) * 1987-04-15 1989-12-01 Roussel Uclaf Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
HUT70187A (en) * 1991-04-11 1995-09-28 Schering Corp Process for preparing oxadiazepine derivatives condensed with indole and pharmaceutical compositions of anti-tumor and anti-psoriatic activity containing said compounds
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
GR3037087T3 (en) 2002-01-31
DE69428025D1 (de) 2001-09-27
YU49200B (sh) 2004-09-03
HUT71130A (en) 1995-11-28
SG63570A1 (en) 1999-03-30
HU219709B (hu) 2001-06-28
JPH07215977A (ja) 1995-08-15
FI945706A7 (sv) 1995-06-08
US5698578A (en) 1997-12-16
CN1055089C (zh) 2000-08-02
HK1013827A1 (en) 1999-09-10
NO944643D0 (no) 1994-12-02
RU2147304C1 (ru) 2000-04-10
CA2137203A1 (en) 1995-06-08
CY2413B1 (en) 2004-11-12
MY125587A (en) 2006-08-30
DK0657458T3 (da) 2001-10-29
FI20011109L (sv) 2001-05-28
KR950018010A (ko) 1995-07-22
BR9404831A (pt) 1995-08-08
IL111850A (en) 2002-11-10
PL182124B1 (pl) 2001-11-30
CA2137203C (en) 2006-11-28
ES2162843T3 (es) 2002-01-16
JP2004269543A (ja) 2004-09-30
CZ291950B6 (cs) 2003-06-18
KR100340159B1 (ko) 2002-11-23
ATE204579T1 (de) 2001-09-15
HU9403468D0 (en) 1995-02-28
NO308798B1 (no) 2000-10-30
NZ270048A (en) 1996-11-26
CZ301894A3 (en) 1995-06-14
FI108138B (sv) 2001-11-30
IL111850A0 (en) 1995-03-15
DE69428025T2 (de) 2002-05-29
CO4340622A1 (es) 1996-07-30
PT657458E (pt) 2002-02-28
EP0657458A1 (en) 1995-06-14
EP0657458B1 (en) 2001-08-22
YU70494A (sh) 1997-03-07
CN1111247A (zh) 1995-11-08
NO944643L (no) 1995-06-08
AU7918894A (en) 1995-06-15
AU687909B2 (en) 1998-03-05
JP3581731B2 (ja) 2004-10-27
FI20011109A7 (sv) 2001-05-29
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
CN1050844C (zh) 2000-03-29
UA44690C2 (uk) 2002-03-15
FI945706A0 (sv) 1994-12-02
TW425397B (en) 2001-03-11
RU94042922A (ru) 1996-12-27
CN1220266A (zh) 1999-06-23

Similar Documents

Publication Publication Date Title
FI20000516A7 (sv) Bis-indolylmaleimidderivat samt deras framställning
FI961599A7 (sv) 1N-alkyl-N-arylpyrimidinaminer och derivat därav
FI941137A7 (sv) 2-debensoyl-2-acyltaxolderivat och förfaranden för framställning av dessa
FI935074A7 (sv) Nya tiopyranopyrrolderivat och framställning av dem
FI935072A7 (sv) Nya perhydroisoindoler och deras framställning
FI953666L (sv) Heterocykliska föreningar och deras framställning och användning
FI953479A0 (sv) 1-arylpyrimidinderivat och farmaceutisk användning av dessa
FI924747A7 (sv) PEG-imidat och proteinderivat därav
FI954131A7 (sv) Heterocykliska föreningar och deras framställning och användning
FI932103A7 (sv) Nya 4-arylpiperaziner och 4-arylpiperidiner
FI945900A7 (sv) Bensensulfoamidderivat och förfarande för deras framställning
FI945625L (sv) Indolkarbazol-imider och deras användning
FI943345L (sv) Organalumoxanprodukter och deras användning
FI940904A7 (sv) Oxazolidindionderivat, deras framställning och användning
FI914826A7 (sv) Kinazolinderivat och deras framställning
FI954130A7 (sv) Heterocykliska föreningar och deras framställning och användning
FI943912A7 (sv) Tienopyrimidinderivat, deras framställning och användning
FI953919A7 (sv) Pyrrolydenmetylderivat och förfarande för deras framställning
FI935728A7 (sv) Substituerade 4-fenylpyridoner och 4-fenyl-2-alkoxipyridiner
FI902597A7 (sv) Bensocykloalkanderivat och deras framställning
FI906425A7 (sv) Kinazolinderivat och deras framställning
FI943734A0 (sv) Nya makrolider och deras användning
FI942294A7 (sv) Bensopyranderivat och deras användning
FI955679A7 (sv) Piperidinderivater, framställning och användning därav
FI981359L (sv) Nya tiomarinolderivat och förfaranden för framställning av dessa